Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01815827 · ClinicalTrials.gov registry record · Phase 1

A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers

A Phase 1 study, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 1
Development phase
62
Enrollment target

NCT01815827: Completed Phase 1 study, sponsored by Hoffmann-La Roche.

NCT01815827 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 62 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01815827, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 1
Development phase
62 participants
Enrollment target

Study Summary

This open-label, parallel group study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of inclacumab in Japanese healthy volunteers compared to Caucasian healthy volunteers. Subjects will receive a single intravenous dose of inclacumab. Follow-up will be for up to 197 days.

Interventions

  • DRUG inclacumab

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2013-06
Est. Completion 2014-02
Phase Phase 1
Hoffmann-La Roche

909 total trials

What the finished NCT01815827 record still lists

NCT01815827 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.

The record links to 0 conditions, and to 1 intervention - of which inclacumab is the first listed.

NCT01815827 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01815827 about?

NCT01815827 is a clinical study titled "A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers". This open-label, parallel group study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of inclacumab in Japanese healthy volunteers compared to Caucasian healthy volunteers. Subjects will receive a single intravenous dose of inclacumab. Follow-up will be ...

What is the current status of trial NCT01815827?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2013-06. Estimated completion is 2014-02.

What interventions are being tested in trial NCT01815827?

The interventions under investigation include: inclacumab (DRUG).

Who is sponsoring clinical trial NCT01815827?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01815827's enrollment target sits among peer trials

62 824th of 2000 higher than 1,173 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03231150 · 62 participants · NA

    Plantar Fasciitis Randomized Clinical Control Trial

  • NCT03458676 · 62 participants · NA

    Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

  • NCT03596086 · 62 participants · Phase 1

    HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

  • NCT03603405 · 62 participants · Phase 1

    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01815827, the US trial registry maintained by the National Library of Medicine. NCT01815827 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.